Divisions of Preventive Medicine (B.M.E., M.V.M., J.T.T., N.R.C., C.M.A.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Cardiovascular Medicine (B.M.E.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Circulation. 2020 Sep 22;142(12):1148-1158. doi: 10.1161/CIRCULATIONAHA.120.046947. Epub 2020 Jul 23.
The majority of sudden cardiac deaths (SCDs) occur in low-risk populations often as the first manifestation of cardiovascular disease (CVD). Biomarkers are screening tools that may identify subclinical cardiovascular disease and those at elevated risk for SCD. We aimed to determine whether the total to high-density lipoprotein cholesterol ratio, high-sensitivity cardiac troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity C-reactive protein individually or in combination could identify individuals at higher SCD risk in large, free-living populations with and without cardiovascular disease.
We performed a nested case-control study within 6 prospective cohort studies using 565 SCD cases matched to 1090 controls (1:2) by age, sex, ethnicity, smoking status, and presence of cardiovascular disease.
The median study follow-up time until SCD was 11.3 years. When examined as quartiles or continuous variables in conditional logistic regression models, each of the biomarkers was significantly and independently associated with SCD risk after mutually controlling for cardiac risk factors and other biomarkers. The mutually adjusted odds ratios for the top compared with the bottom quartile were 1.90 (95% CI, 1.30-2.76) for total to high-density lipoprotein cholesterol ratio, 2.59 (95% CI, 1.76-3.83) for high-sensitivity cardiac troponin I, 1.65 (95% CI, 1.12-2.44) for NT-proBNP, and 1.65 (95% CI, 1.13-2.41) for high-sensitivity C-reactive protein. A biomarker score that awarded 1 point when the concentration of any of those 4 biomarkers was in the top quartile (score range, 0-4) was strongly associated with SCD, with an adjusted odds ratio of 1.56 (95% CI, 1.37-1.77) per 1-unit increase in the score.
Widely available measures of lipids, subclinical myocardial injury, myocardial strain, and vascular inflammation show significant independent associations with SCD risk in apparently low-risk populations. In combination, these measures may have utility to identify individuals at risk for SCD.
大多数心源性猝死(SCD)发生在低危人群中,通常是心血管疾病(CVD)的首次表现。生物标志物是筛查工具,可识别亚临床心血管疾病和 SCD 风险升高的人群。我们旨在确定总胆固醇与高密度脂蛋白胆固醇比值、高敏心肌肌钙蛋白 I、NT-proBNP(N 末端脑利钠肽前体)或高敏 C 反应蛋白单独或联合应用是否可以识别患有和不患有 CVD 的大型自由生活人群中 SCD 风险较高的个体。
我们在 6 项前瞻性队列研究中进行了嵌套病例对照研究,使用 565 例 SCD 病例和 1090 例对照(1:2),通过年龄、性别、种族、吸烟状况和心血管疾病的存在进行匹配。
中位研究随访时间直到 SCD 为 11.3 年。在条件逻辑回归模型中作为四分位数或连续变量进行检查时,在相互控制心脏危险因素和其他生物标志物后,每种生物标志物均与 SCD 风险显著独立相关。与最低四分位相比,最高四分位的相互调整比值比分别为总胆固醇与高密度脂蛋白胆固醇比值 1.90(95%CI,1.30-2.76)、高敏心肌肌钙蛋白 I 2.59(95%CI,1.76-3.83)、NT-proBNP 1.65(95%CI,1.12-2.44)和高敏 C 反应蛋白 1.65(95%CI,1.13-2.41)。当 4 种生物标志物中任何一种的浓度处于最高四分位时,生物标志物评分得 1 分(评分范围为 0-4),与 SCD 强烈相关,评分每增加 1 分,调整后的比值比为 1.56(95%CI,1.37-1.77)。
广泛可用的血脂、亚临床心肌损伤、心肌应变和血管炎症测量值与低危人群中的 SCD 风险具有显著独立关联。这些措施结合使用可能有助于识别 SCD 风险个体。